SKIN CLEARANCE AND AFFECTED BSA AT WEEK 52

PATIENTS ACHIEVING IGA SCORES OF 0/1 THROUGH WEEK 521

PATIENTS ACHIEVING IGA SCORES OF 0/1 THROUGH WEEK 521

This table shows the percentage of patients who achieved an IGA score of 0 or 1 through week 52 of the study. 75.4% and 80.1% of patients who received OPZELURA during the control and extension periods of TRuE-AD1 and TRuE-AD2 achieved an IGA score of 0 or 1, respectively. 73.7% and 74.4% of patients who received vehicle during the control period of TRuE-AD1 and TRuE-AD2 but then switched to OPZELURA during the extension period achieved an IGA score of 0 or 1, respectively.
This table shows the percentage of patients who achieved an IGA score of 0 or 1 through week 52 of the study. 75.4% and 80.1% of patients who received OPZELURA during the control and extension periods of TRuE-AD1 and TRuE-AD2 achieved an IGA score of 0 or 1, respectively. 73.7% and 74.4% of patients who received vehicle during the control period of TRuE-AD1 and TRuE-AD2 but then switched to OPZELURA during the extension period achieved an IGA score of 0 or 1, respectively.

*IGA is assessed on a severity scale of 0-4.2

BSA=body surface area; IGA=Investigator’s Global Assessment.

>70% of patients had clear or almost clear skin with as-needed use of OPZELURA at week 521
  • More patients achieved an IGA score of 0 or 1 after switching from vehicle to OPZELURA in the 44-week extension period1*
>70% of patients had clear or almost clear skin with as-needed use of OPZELURA at week 521
  • More patients achieved an IGA score of 0 or 1 after switching from vehicle to OPZELURA in the 44-week extension period1*
  • Data were reported as observed1
  • No conclusions of safety or efficacy should be made based on these results
  • Number of patients in each study arm are displayed below the graph for each study visit
  • OPZELURA is for short-term and non-continuous use only2

*IGA is assessed on a severity scale of 0-4.2

BSA=body surface area; IGA=Investigator’s Global Assessment.

Learn about dosing and administration >

References: 1. Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. Presented at: Revolutionizing Atopic Dermatitis Virtual Conference; June 13, 2021. 2. Opzelura. Prescribing Information. Incyte Corporation; 2022.

AFFECTED BSA REDUCTION THROUGH WEEK 521

AFFECTED BSA REDUCTION THROUGH WEEK 521

This table shows the percent reduction in BSA patients experienced through week 52 of the study. Patients who received OPZELURA during the control and extension periods of TRuE-AD1 and TRuE-AD2 achieved a 1.5% and 1.4% reduction in affected BSA, respectively. Patients who received vehicle during the control period of TRuE-AD1 and TRuE-AD2 but then switched to OPZELURA during the extension period achieved a 1.0% and 2.2% reduction in affected BSA, respectively.
This table shows the percent reduction in BSA patients experienced through week 52 of the study. Patients who received OPZELURA during the control and extension periods of TRuE-AD1 and TRuE-AD2 achieved a 1.5% and 1.4% reduction in affected BSA, respectively. Patients who received vehicle during the control period of TRuE-AD1 and TRuE-AD2 but then switched to OPZELURA during the extension period achieved a 1.0% and 2.2% reduction in affected BSA, respectively.

BSA=body surface area.

Mean total affected BSA was reduced in patients who switched from vehicle to OPZELURA in the 44-week extension period1
Mean total affected BSA was reduced in patients who switched from vehicle to OPZELURA in the 44-week extension period1
  • Data were reported as observed1
  • No conclusions of safety or efficacy should be made based on these results
  • Number of patients in each study arm are displayed below the graph for each study visit
  • OPZELURA is for short-term and non-continuous use only2

BSA=body surface area.

Learn about dosing and administration >

References: 1. Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. Presented at: Revolutionizing Atopic Dermatitis Virtual Conference; June 13, 2021. 2. Opzelura. Prescribing Information. Incyte Corporation; 2022.